Abstract: The present invention relates to compounds having the formula (I) and their use in clinical and industrial diagnosis.

Abstract: The present invention relates to compounds having the formula (I) and their use in clinical and industrial diagnosis.

Abstract: The present invention relates to a novel method for preparing compounds having the formula (I), where X is biotin or Y being biotin or Z being biotin or V being biotin or It also relates to compounds having the formula (I) and their use in clinical and industrial diagnosis.

Abstract: The present invention relates to a novel method for preparing compounds having the formula (I), where X is biotin or Y being biotin or Z being biotin or V being biotin or It also relates to compounds having the formula (I) and their use in clinical and industrial diagnosis.

Abstract: The present invention concerns coupling agents having the following general formula: activated intermediates consisting of a coupling agent such as defined above with either a molecule having on its surface at least one aldehyde and/or ketone function before conjugation, or with one to eight molecules having on their surface at least one free thiol function before conjugation, conjugates consisting of a coupling agent such as defined above, of a molecule having on its surface at least one aldehyde and/or ketone function and of one to eight molecules having on their surface at least one free thiol function, and the use of said conjugates for in vitro diagnostic methods of diseases involving recognition of a ligand-anti-ligand pair.

Abstract: The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising or consisting of the N-terminal end. The invention is characterized in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in ? helix, a second peptide fragment having secondary structure in ? helix and a third peptide bond fragment linking the two ? helices, these two ? helices being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all of part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.

Abstract: The present invention concerns coupling agents having the following general formula: activated intermediates consisting of a coupling agent such as defined above with either a molecule having on its surface at least one aldehyde and/or ketone function before conjugation, or with one to eight molecules having on their surface at least one free thiol function before conjugation, conjugates consisting of a coupling agent such as defined above, of a molecule having on its surface at least one aldehyde and/or ketone function and of one to eight molecules having on their surface at least one free thiol function, and the use of said conjugates for in vitro diagnostic methods of diseases involving recognition of a ligand-anti-ligand pair.

Abstract: The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising or consisting of the N-terminal end. The invention is characterized in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in &agr; helix, a second peptide fragment having secondary structure in &agr; helix and a third peptide bond fragment linking the two &agr; helices, these two &agr; helices being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all of part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.

Abstract: The invention concerns a structural peptide, identified by antibodies directed against a polypeptide, comprising the 2-45 amino acid sequence of the N-terminal end of the Core or nucleocapsid (p21) protein of the hepatitis C virus (HCV), excluding any protein or peptide compound comprising or consisting of the N-terminal end. The invention is characterized in that it comprises a tertiary structure consisting of at least a first peptide fragment having a secondary structure in &agr; helix, a second peptide fragment having secondary structure in &agr; helix and a third peptide bond fragment linking the two &agr; helices, these two &agr; helices being substantially perpendicular to each other in space. This peptide can be used for detecting antibodies directed against the p21 protein of HCV, for detecting all of part of the RNA of HCV and for preparing a diagnostic, prophylactic or therapeutic composition for detecting, preventing or treating an HCV infection.